{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:19:56Z","timestamp":1791652796799,"version":"4.3.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Samsung Bioepis"},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2024-00438476"],"award-info":[{"award-number":["RS-2024-00438476"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40259-025-00707-3","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:33:27Z","timestamp":1740148407000},"page":"281-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-4676","authenticated-orcid":false,"given":"Jun Ho","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinah","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin G.","family":"Kulasekararaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"11","key":"707_CR1","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256\u201364. https:\/\/doi.org\/10.1038\/nbt1344.","journal-title":"Nat Biotechnol"},{"key":"707_CR2","unstructured":"US Food and Drug Administration. Approval package for application number: 125166s431. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/125166Orig1s431.pdf. Accessed 8 Aug 2024."},{"key":"707_CR3","unstructured":"European Medicines Agency. Soliris (eculizumab): an overview of Soliris and why it is authorised in the EU 2009. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/soliris-epar-medicine-overview_en.pdf. Accessed 8 Aug 2024."},{"issue":"7","key":"707_CR4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","volume":"58","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Ter Heine R, Moes D, Langemeijer S, Schols SEM, Volokhina EB, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet. 2019;58(7):859\u201374. https:\/\/doi.org\/10.1007\/s40262-019-00742-8.","journal-title":"Clin Pharmacokinet"},{"key":"707_CR5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2147\/TCRM.S96720","volume":"12","author":"F Al-Ani","year":"2016","unstructured":"Al-Ani F, Chin-Yee I, Lazo-Langner A. Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. Ther Clin Risk Manag. 2016;12:1161\u201370. https:\/\/doi.org\/10.2147\/TCRM.S96720.","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"707_CR6","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1182\/blood-2007-04-083170","volume":"110","author":"VP Ferreira","year":"2007","unstructured":"Ferreira VP, Pangburn MK. Factor H\u2013mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Blood. 2007;110(6):2190\u20132. https:\/\/doi.org\/10.1182\/blood-2007-04-083170.","journal-title":"Blood"},{"key":"707_CR7","doi-asserted-by":"publisher","first-page":"263300402095934","DOI":"10.1177\/2633004020959349","volume":"1","author":"M Griffin","year":"2020","unstructured":"Griffin M, Kelly R, Pike A. A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going? Ther Adv Rare Dis. 2020;1:2633004020959349.","journal-title":"Ther Adv Rare Dis."},{"issue":"2","key":"707_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Socie","year":"2019","unstructured":"Socie G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297\u2013310. https:\/\/doi.org\/10.1111\/bjh.15790.","journal-title":"Br J Haematol"},{"issue":"25","key":"707_CR9","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786\u201392. https:\/\/doi.org\/10.1182\/blood-2011-02-333997.","journal-title":"Blood"},{"issue":"11","key":"707_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1159\/000508920","volume":"144","author":"AI Avila Bernabeu","year":"2020","unstructured":"Avila Bernabeu AI, Cavero Escribano T, Cao VM. Atypical hemolytic uremic syndrome: new challenges in the complement blockage era. Nephron. 2020;144(11):537\u201349. https:\/\/doi.org\/10.1159\/000508920.","journal-title":"Nephron"},{"issue":"1","key":"707_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1182\/asheducation-2016.1.217","volume":"2016","author":"V Afshar-Kharghan","year":"2016","unstructured":"Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology. 2016;2016(1):217\u201325. https:\/\/doi.org\/10.1182\/asheducation-2016.1.217.","journal-title":"Hematology"},{"issue":"2","key":"707_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5551\/jat.RV17026","volume":"26","author":"Y Yoshida","year":"2019","unstructured":"Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of atypical hemolytic uremic syndrome. J Atheroscler Thromb. 2019;26(2):99\u2013110. https:\/\/doi.org\/10.5551\/jat.RV17026.","journal-title":"J Atheroscler Thromb"},{"issue":"11","key":"707_CR13","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s00467-018-4091-3","volume":"34","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar N. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019;34(11):2261\u201377. https:\/\/doi.org\/10.1007\/s00467-018-4091-3.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"707_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.chest.2017.03.055","volume":"152","author":"E Azoulay","year":"2017","unstructured":"Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, et al. Expert statements on the standard of care in criticallyiIll adult patients with atypical hemolytic uremic syndrome. Chest. 2017;152(2):424\u201334. https:\/\/doi.org\/10.1016\/j.chest.2017.03.055.","journal-title":"Chest"},{"issue":"23","key":"707_CR15","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381. https:\/\/doi.org\/10.1056\/NEJMoa1208981.","journal-title":"N Engl J Med"},{"key":"707_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/IJNRD.S215370","volume":"12","author":"R Raina","year":"2019","unstructured":"Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, et al. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis. 2019;12:183\u2013204. https:\/\/doi.org\/10.2147\/IJNRD.S215370.","journal-title":"Int J Nephrol Renovasc Dis."},{"issue":"1","key":"707_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/bjh.15899","volume":"186","author":"L Neave","year":"2019","unstructured":"Neave L, Gale DP, Cheesman S, Shah R, Scully M. Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy. Br J Haematol. 2019;186(1):113\u201324. https:\/\/doi.org\/10.1111\/bjh.15899.","journal-title":"Br J Haematol"},{"issue":"3","key":"707_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","volume":"130","author":"SA Merrill","year":"2017","unstructured":"Merrill SA, Brittingham ZD, Yuan X, Moliterno AR, Sperati CJ, Brodsky RA. Eculizumab cessation in atypical hemolytic uremic syndrome. Blood. 2017;130(3):368\u201372. https:\/\/doi.org\/10.1182\/blood-2017-02-770214.","journal-title":"Blood"},{"key":"707_CR19","doi-asserted-by":"publisher","unstructured":"Caetano R, Cordeiro Dias Villela Correa M, Villardi P, Almeida Rodrigues PH, Garcia Serpa Osorio-de-Castro C. Dynamics of patents, orphan drug designation, licensing, and revenues from drugs for rare diseases: the market expansion of eculizumab. PLoS One. 2021;16(3):e0247853. https:\/\/doi.org\/10.1371\/journal.pone.0247853.","DOI":"10.1371\/journal.pone.0247853"},{"key":"707_CR20","unstructured":"IQVIA. The impact of biosimilar competition in Europe 2023. 2023. Available from: https:\/\/www.iqvia.com\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2023. Accessed 12 Aug 2024."},{"issue":"2","key":"707_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay J, Schoels MM, Dorner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165\u201374. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211937.","journal-title":"Ann Rheum Dis"},{"key":"707_CR22","doi-asserted-by":"publisher","first-page":"175628481984274","DOI":"10.1177\/1756284819842748","volume":"12","author":"A Milassin","year":"2019","unstructured":"Milassin A, Fabian A, Molnar T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therap Adv Gastroenterol. 2019;12:1756284819842748. https:\/\/doi.org\/10.1177\/1756284819842748.","journal-title":"Therap Adv Gastroenterol."},{"key":"707_CR23","doi-asserted-by":"publisher","unstructured":"Kvien TK PK, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheumatol. 2022;52(151939). https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.009","DOI":"10.1016\/j.semarthrit.2021.11.009"},{"issue":"193","key":"707_CR24","doi-asserted-by":"publisher","first-page":"eCollection2016","DOI":"10.3389\/fphar.2016.00193","volume":"7","author":"EJEC Moorkens","year":"2016","unstructured":"Moorkens EJEC, Huys I, Declerck P, Simoens S, Vulto AG. Overcoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodies. Front Pharmacol. 2016;7(193):eCollection2016. https:\/\/doi.org\/10.3389\/fphar.2016.00193.","journal-title":"Front Pharmacol"},{"issue":"6","key":"707_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s40259-020-00440-z","volume":"34","author":"LSS Barbier","year":"2022","unstructured":"Barbier LSS, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars. Part II: improving biosimilar use in clinical practice. BioDrugs. 2022;34(6):12. https:\/\/doi.org\/10.1007\/s40259-020-00440-z.","journal-title":"BioDrugs"},{"key":"707_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphar.2019.00279","volume":"10","author":"DC Baumgart","year":"2019","unstructured":"Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. https:\/\/doi.org\/10.3389\/fphar.2019.00279.","journal-title":"Front Pharmacol"},{"key":"707_CR27","unstructured":"World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs), Annex 2, TRS No 977. 2010. Available from: https:\/\/www.who.int\/publications\/m\/item\/sbp-trs-977-Annex-2. Accessed 8 Aug 2024."},{"key":"707_CR28","unstructured":"US Food and Drug Administration. Biosimilars: overview for health care professionals. 2024. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/overview-health-care-professionals. Accessed 26 Nov 2024."},{"key":"707_CR29","unstructured":"European Medicines Agency and European Commission. Biosimilars in the EU: information guide for healthcare professionals. 2019. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 8 Aug 2024."},{"key":"707_CR30","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. 2014. Available from: https:\/\/www.ema.europa.eu\/system\/files\/documents\/scientific-guideline\/wc500176768_en.pdf. Accessed 8 Aug 2024."},{"issue":"2","key":"707_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0300985814547282","volume":"52","author":"AM Ryan","year":"2015","unstructured":"Ryan AM. Frontiers in nonclinical drug development: biosimilars. Vet Pathol. 2015;52(2):419\u201326. https:\/\/doi.org\/10.1177\/0300985814547282.","journal-title":"Vet Pathol"},{"issue":"4","key":"707_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/ph5040353","volume":"5","author":"J Wang","year":"2012","unstructured":"Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals (Basel). 2012;5(4):353\u201368. https:\/\/doi.org\/10.3390\/ph5040353.","journal-title":"Pharmaceuticals (Basel)"},{"key":"707_CR33","unstructured":"US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: update. 2024. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-update. Accessed 8 Aug 2024."},{"key":"707_CR34","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, revision 1. 2015. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf. Accessed 27 Jun 2024."},{"key":"707_CR35","unstructured":"US Food and Drug Administration. Biosimilar development, review, and approval. 2022. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-development-review-and-approval. Accessed 27 Jun 2024."},{"issue":"1","key":"707_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/pharmaceutics13010048","volume":"13","author":"I Gherghescu","year":"2020","unstructured":"Gherghescu I, Delgado-Charro MB. The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. Pharmaceutics. 2020;13(1):48. https:\/\/doi.org\/10.3390\/pharmaceutics13010048.","journal-title":"Pharmaceutics"},{"issue":"26","key":"707_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2012-04-425744","volume":"120","author":"MBM Weise","year":"2012","unstructured":"Weise MBM, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):7. https:\/\/doi.org\/10.1182\/blood-2012-04-425744.","journal-title":"Blood"},{"key":"707_CR38","unstructured":"European Medicines Agency. ICH Q5E: comparability of biotechnological\/biological products subject to changes in their manufacturing process. 2005. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-5-e-comparability-biotechnologicalbiological-products-step-5_en.pdf (2005). Accessed 8 Aug 2024."},{"key":"707_CR39","unstructured":"European Medicines Agency. Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process. 2007. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-comparability-biotechnology-derived-medicinal-products-after-change-manufacturing-process_en.pdf. Accessed 22 Jun 2024."},{"key":"707_CR40","unstructured":"US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. Available from: https:\/\/www.fda.gov\/media\/179456\/download. Accessed 26 Nov 2024."},{"key":"707_CR41","unstructured":"US Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product: guidance for industry. 2016. Available from: https:\/\/www.fda.gov\/media\/88622\/download. Accessed 26 Nov 2024."},{"key":"707_CR42","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues: revision 1. 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf. Accessed 26 Nov 2024."},{"issue":"10","key":"707_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02953","volume":"38","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, Mainwaring PN, Curigliano G, Pegram M, Latymer M, Bair AH, et al. Understanding the role of comparative clinical studies in the development of oncology biosimilars. J Clin Oncol. 2020;38(10): 107080. https:\/\/doi.org\/10.1200\/JCO.19.02953.","journal-title":"J Clin Oncol"},{"issue":"1","key":"707_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13023-018-0931-2","volume":"13","author":"S Day","year":"2018","unstructured":"Day S, Jonker AH, Lau LPL, Hilgers RD, Irony I, Larsson K, et al. Recommendations for the design of small population clinical trials. Orphanet J Rare Dis. 2018;13(1):195. https:\/\/doi.org\/10.1186\/s13023-018-0931-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"707_CR45","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.drudis.2019.01.005","volume":"24","author":"DA Fonseca","year":"2019","unstructured":"Fonseca DA, Amaral I, Pinto AC, Cotrim MD. Orphan drugs: major development challenges at the clinical stage. Drug Discov Today. 2019;24(3):867\u201372.","journal-title":"Drug Discov Today"},{"issue":"6","key":"707_CR46","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40259-023-00631-4","volume":"37","author":"N Kirsch-Stefan","year":"2023","unstructured":"Kirsch-Stefan N, Guillen E, Ekman N, Barry S, Knippel V, Killalea S, et al. Do the outcomes of clinical efficacy trials matter in regulatory decision-making for biosimilars? BioDrugs. 2023;37(6):855\u201371. https:\/\/doi.org\/10.1007\/s40259-023-00631-4.","journal-title":"BioDrugs"},{"issue":"1","key":"707_CR47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cpt.2785","volume":"113","author":"E Guillen","year":"2023","unstructured":"Guillen E, Ekman N, Barry S, Weise M, Wolff-Holz E. A data driven approach to support tailored clinical programs for biosimilar monoclonal antibodies. Clin Pharmacol Ther. 2023;113(1):108\u201323. https:\/\/doi.org\/10.1002\/cpt.2785.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"707_CR48","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40259-023-00619-0","volume":"37","author":"HP Cohen","year":"2023","unstructured":"Cohen HP, Turner M, McCabe D, Woollett GR. Future evolution of biosimilar development by application of current science and available evidence: the developer\u2019s perspective. BioDrugs. 2023;37(5):583\u201393. https:\/\/doi.org\/10.1007\/s40259-023-00619-0.","journal-title":"BioDrugs"},{"issue":"22","key":"707_CR49","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","volume":"124","author":"M Weise","year":"2014","unstructured":"Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191\u20136. https:\/\/doi.org\/10.1182\/blood-2014-06-583617.","journal-title":"Blood"},{"issue":"15s","key":"707_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/fon-2017-0156","volume":"13","author":"M Ogura","year":"2017","unstructured":"Ogura M, Coiffier B, Kwon HC, Yoon SW. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10. Future Oncol. 2017;13(15s):45\u201353. https:\/\/doi.org\/10.2217\/fon-2017-0156.","journal-title":"Future Oncol"},{"issue":"6","key":"707_CR51","first-page":"14","volume":"34","author":"L Barbier","year":"2020","unstructured":"Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars Part I: improving biosimilar understanding and adoption. BioDrugs. 2020;34(6):14.","journal-title":"BioDrugs"},{"issue":"10","key":"707_CR52","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/14712598.2019.1665017","volume":"19","author":"W Jurczak","year":"2019","unstructured":"Jurczak W, Dlugosz Danecka M, Buske C. Rituximab biosimilars for lymphoma in Europe. Expert Opin Biol Ther. 2019;19(10):1045\u201356. https:\/\/doi.org\/10.1080\/14712598.2019.1665017.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"707_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","volume":"80","author":"H Kim","year":"2020","unstructured":"Kim H, Alten R, Avedano L, Dignass A, Gomollon F, Greveson K, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80(2):99\u2013113. https:\/\/doi.org\/10.1007\/s40265-020-01256-5.","journal-title":"Drugs"},{"issue":"1","key":"707_CR54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/art.40336","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Jaworski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70(1):40\u20138. https:\/\/doi.org\/10.1002\/art.40336.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"707_CR55","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679\u201387.","journal-title":"Ann Rheum Dis"},{"key":"707_CR56","doi-asserted-by":"publisher","unstructured":"Wiland P, Jeka S, Dokoupilova E, Miranda Limon JM, Jauch-Lembach J, Thakur A, et al. A randomized, double-blind, parallel-group, multicenter study to compare the efficacy, safety and immunogenicity of a proposed adalimumab biosimilar (GP2017) with reference adalimumab in patients with moderate-to-severe active rheumatoid arthritis. Arthritis Rheumatol. 2018. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.106","DOI":"10.1016\/j.jaad.2017.04.106"},{"issue":"3","key":"707_CR57","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-019-00355-4","volume":"33","author":"S Bellinvia","year":"2019","unstructured":"Bellinvia S, Cummings JRF, Ardern-Jones MR, Edwards CJ. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019;33(3):241\u201353. https:\/\/doi.org\/10.1007\/s40259-019-00355-4.","journal-title":"BioDrugs"},{"issue":"4","key":"707_CR58","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/APO.0000000000000380","volume":"10","author":"J Sota","year":"2021","unstructured":"Sota J, Gentileschi S, Vitale A, Gaggiano C, De Bartolo G, Bianco MT, et al. Effectiveness of SB5, an adalimumab biosimilar, in patients with noninfectious uveitis: a real-life monocentric experience. Asia Pac J Ophthalmol (Phila). 2021;10(4):360\u20135. https:\/\/doi.org\/10.1097\/APO.0000000000000380.","journal-title":"Asia Pac J Ophthalmol (Phila)."},{"issue":"1","key":"707_CR59","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/ibd\/izab027","volume":"28","author":"G Tapete","year":"2022","unstructured":"Tapete G, Bertani L, Pieraccini A, Lynch EN, Giannotta M, Morganti R, et al. Effectiveness and safety of nonmedical switch from adalimumab originator to SB5 biosimilar in patients with inflammatory bowel diseases: twelve-month follow-up from the TABLET Registry. Inflamm Bowel Dis. 2022;28(1):62\u20139. https:\/\/doi.org\/10.1093\/ibd\/izab027.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"707_CR60","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/14712598.2022.2012146","volume":"22","author":"JP Gisbert","year":"2022","unstructured":"Gisbert JP, Gaffney K, Young D, Ebbers HC, Girolomoni G. Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi\u2122): a multidisciplinary perspective. Expert Opin Biol Ther. 2022;22(2):109\u201321. https:\/\/doi.org\/10.1080\/14712598.2022.2012146.","journal-title":"Expert Opin Biol Ther"},{"key":"707_CR61","unstructured":"European Medicines Agency. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf. Accessed 6 Jul 2024.]"},{"issue":"16","key":"707_CR62","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s40265-021-01610-1","volume":"81","author":"E Mysler","year":"2021","unstructured":"Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, et al. Biosimilar-to-biosimilar switching: what is the rationale and current experience? Drugs. 2021;81(16):1859\u201379. https:\/\/doi.org\/10.1007\/s40265-021-01610-1.","journal-title":"Drugs"},{"issue":"4","key":"707_CR63","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734\u201355. https:\/\/doi.org\/10.1002\/cpt.1836.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"707_CR64","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40259-022-00546-6","volume":"36","author":"HP Cohen","year":"2022","unstructured":"Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, Blauvelt A. Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. BioDrugs. 2022;36(5):625\u201337.","journal-title":"BioDrugs"},{"issue":"3","key":"707_CR65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40259-024-00655-4","volume":"38","author":"HP Cohen","year":"2024","unstructured":"Cohen HP, Bodenmueller W. Additional data in expanded patient populations and new indications support the practice of biosimilar-to-biosimilar switching. BioDrugs. 2024;38(3):331\u20139. https:\/\/doi.org\/10.1007\/s40259-024-00655-4.","journal-title":"BioDrugs"},{"issue":"10","key":"707_CR66","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.drudis.2019.06.016","volume":"24","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, Schellekens H. Are we ready to close the discussion on the interchangeability of biosimilars? Drug Discov Today. 2019;24(10):1963\u20137. https:\/\/doi.org\/10.1016\/j.drudis.2019.06.016.","journal-title":"Drug Discov Today"},{"issue":"2","key":"707_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14712598.2021.1958778","volume":"22","author":"FS Macaluso","year":"2022","unstructured":"Macaluso FS, Cummings JF, Atreya R, Choi J, Orlando A. A systematic review on infliximab biosimilar SB2: from pre-clinical data to real-world evidence. Expert Opin Biol Ther. 2022;22(2):203\u201323. https:\/\/doi.org\/10.1080\/14712598.2021.1958778.","journal-title":"Expert Opin Biol Ther"},{"key":"707_CR68","unstructured":"European Medicines Agency. Epysqli SmPC. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/epysqli-epar-product-information_en.pdf. Accessed 26 Nov 2024."},{"key":"707_CR69","unstructured":"European Medicines Agency. Bekemv SmPC. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bekemv-epar-product-information_en.pdf. Accessed 27 Nov 2024."},{"key":"707_CR70","unstructured":"US Food and Drug Administration. Epysqli highlights of prescribing information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761340s003lbl.pdf. Accessed 27 Nov 2024."},{"key":"707_CR71","unstructured":"US Food and Drug Administration. Bkemv highlights of prescribing information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761333s001lbl.pdf (2024). Accessed 26 Nov 2024."},{"key":"707_CR72","unstructured":"UK MHRA. Epysqli SmPC. 2024. Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/f49bdde4b6c2546eacebcf41f2ddbfca07af1da1. Accessed 26 Nov 2024."},{"key":"707_CR73","unstructured":"UK MHRA. Bekemv SmPC. 2024. Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/94c1a741bd3ed27da2a0eb9c22767766c7505f86. Accessed 26 Nov 2024."},{"key":"707_CR74","unstructured":"Korea Ministry of Food and Drug Safety. Epysqli product information. Available from: https:\/\/www.health.kr\/searchDrug\/result_drug.asp?drug_cd=2024012200003. Accessed 8 Aug 2024."},{"key":"707_CR75","unstructured":"Russian Ministry of Health. Elizaria SmpC. 2021. Available from: https:\/\/www.generium.ru\/upload\/iblock\/018\/0geas93do3809knr3v02i7a8l5dks0rs.pdf. Accessed 27 Nov 2024."},{"issue":"Suppl. 1","key":"707_CR76","doi-asserted-by":"publisher","first-page":"11049","DOI":"10.1182\/blood-2022-166295","volume":"140","author":"JH Jang","year":"2022","unstructured":"Jang JH, Hong E, Kim H, Kim Y, Yoo T, Lee J. Characterization for the similarity assessment between SB12 (eculizumab biosimilar) and eculizumab using state-of-the-art analytical method. Blood. 2022;140(Suppl. 1):11049. https:\/\/doi.org\/10.1182\/blood-2022-166295.","journal-title":"Blood"},{"issue":"5","key":"707_CR77","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40259-021-00492-9","volume":"35","author":"KM Hutterer","year":"2021","unstructured":"Hutterer KM, Ip A, Kuhns S, Cao S, Wikstrom M, Liu J. Analytical similarity assessment of ABP 959 in comparison with eculizumab reference product. BioDrugs. 2021;35(5):563\u201377. https:\/\/doi.org\/10.1007\/s40259-021-00492-9.","journal-title":"BioDrugs"},{"key":"707_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115004","volume":"220","author":"V Gusarova","year":"2022","unstructured":"Gusarova V, Degterev M, Lyagoskin I, Simonov V, Smolov M, Taran S, et al. Analytical and functional similarity of biosimilar Elizaria\u00ae with eculizumab reference product. J Pharm Biomed Anal. 2022;220: 115004. https:\/\/doi.org\/10.1016\/j.jpba.2022.115004.","journal-title":"J Pharm Biomed Anal"},{"key":"707_CR79","unstructured":"European Medicines Agency. Epysqli EPAR. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/epysqli-epar-public-assessment-report_en.pdf. Accessed 6 Jan 2025."},{"issue":"6","key":"707_CR80","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5414\/CP204176","volume":"60","author":"HA Lee","year":"2022","unstructured":"Lee HA, Jang H, Jeong D, Kim Y, Fuhr R. A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects. Int J Clin Pharmacol Ther. 2022;60(6):269\u201379. https:\/\/doi.org\/10.5414\/CP204176.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"707_CR81","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jha2.632","volume":"4","author":"JH Jang","year":"2023","unstructured":"Jang JH, Gomez RD, Bumbea H, Nogaieva L, Wong LLL, Lim SM, et al. A phase III, randomised, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria. EJHaem. 2023;4(1):26\u201336. https:\/\/doi.org\/10.1002\/jha2.632.","journal-title":"EJHaem."},{"issue":"Suppl. 1","key":"707_CR82","doi-asserted-by":"publisher","first-page":"8658","DOI":"10.1182\/blood-2022-158387","volume":"140","author":"JH Jang","year":"2022","unstructured":"Jang JH, Demichelis R, Nogaieva L, Wong LL, Lim SM, Kim Y, et al. Sensitivity analysis on the primary efficacy results of SB12 (eculizumab biosimilar) phase III study in paroxysmal nocturnal hemoglobinuria patients. Blood. 2022;140(Suppl. 1):8658\u20139. https:\/\/doi.org\/10.1182\/blood-2022-158387.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"707_CR83","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1182\/blood-2023-191275","volume":"142","author":"JH Jang","year":"2023","unstructured":"Jang JH, Lim SM, Tomuleasa C, Oliynyk H, Lanamtieng T, Park J, et al. Efficacy of SB12 (eculizumab biosimilar) in Asian and non-Asian patients with paroxysmal nocturnal hemoglobinuria: aubgroup analysis of a global phase III randomized controlled trial. Blood. 2023;142(Suppl. 1):2727. https:\/\/doi.org\/10.1182\/blood-2023-191275.","journal-title":"Blood"},{"issue":"1","key":"707_CR84","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/ejh.13411","volume":"105","author":"V Chow","year":"2020","unstructured":"Chow V, Pan J, Chien D, Mytych DT, Hanes V. A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris\u00ae) in healthy male subjects. Eur J Haematol. 2020;105(1):66\u201374. https:\/\/doi.org\/10.1111\/ejh.13411.","journal-title":"Eur J Haematol"},{"issue":"Suppl. 1","key":"707_CR85","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1182\/blood-2023-186362","volume":"142","author":"A Kulasekararaj","year":"2023","unstructured":"Kulasekararaj A, Lanza F, Arvanitakis A, Langemeijer SM, Chonat S, Cao J, et al. Efficacy of parallel and crossover analysis as well as pharmacokinetic similarity were confirmed between ABP 959 and eculizumab reference product in patients with PNH. Blood. 2023;142(Suppl. 1):4092. https:\/\/doi.org\/10.1182\/blood-2023-186362.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"707_CR86","doi-asserted-by":"publisher","first-page":"8660","DOI":"10.1182\/blood-2022-166722","volume":"140","author":"A Kulasekararaj","year":"2022","unstructured":"Kulasekararaj A, Lanza F, Arvanitakis A, Langemeijer SMC, Chonat S, Chow V, et al. Efficacy and safety of biosimilar candidate ABP 959 as compared with eculizumab reference product in paroxysmal nocturnal hemoglobinuria. Blood. 2022;140(Suppl. 1):8660\u20132. https:\/\/doi.org\/10.1182\/blood-2022-166722.","journal-title":"Blood"},{"issue":"11","key":"707_CR87","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1007\/s00277-021-04624-7","volume":"100","author":"AD Kulagin","year":"2021","unstructured":"Kulagin AD, Ptushkin VV, Lukina EA, Davydkin IL, Korobkin AV, Shamrai VS, et al. Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab. Ann Hematol. 2021;100(11):2689\u201398. https:\/\/doi.org\/10.1007\/s00277-021-04624-7.","journal-title":"Ann Hematol"},{"key":"707_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2023-186362","volume":"142","author":"A Kulasekararaj","year":"2023","unstructured":"Kulasekararaj A. Efficacy of parallel and crossover analysis as well as pharmacokinetic similarity were confirmed between ABP 959 and eculizumab reference product in patients with PNH. Blood. 2023;142:1.","journal-title":"Blood"},{"key":"707_CR89","unstructured":"European Commission. Excipients in the labelling and package leaflet of medicinal products for human use. Annex to the European Commission guideline. 2018. Available from: https:\/\/www.ema.europa.eu\/en\/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use. Accessed 8 Aug 2024."},{"issue":"4","key":"707_CR90","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000702","volume":"6","author":"MM Piggin","year":"2022","unstructured":"Piggin MM. Addressing inequality of access to biologics: what is your role? A patient (advocate)\u2019s perspective on biosimilars. Hemasphere. 2022;6(4): e702. https:\/\/doi.org\/10.1097\/HS9.0000000000000702.","journal-title":"Hemasphere."},{"issue":"8","key":"707_CR91","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1007\/s12325-021-01825-4","volume":"38","author":"WY Cheng","year":"2021","unstructured":"Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian M, Mahendran M, et al. Real-world healthcare resource utilization (HRU) and costs of patients with paroxysmal nocturnal hemoglobinuria (PNH) receiving eculizumab in a US population. Adv Ther. 2021;38(8):4461\u201379. https:\/\/doi.org\/10.1007\/s12325-021-01825-4.","journal-title":"Adv Ther"},{"key":"707_CR92","unstructured":"NHS England: The NHS saves \u00a3324 million in a year by switching to better value medicines. 2018. Available from: https:\/\/www.england.nhs.uk\/2018\/07\/nhs-saves-324-million-year-switching-to-better-value-medicines\/. Accessed 28 Nov 2024."},{"issue":"6","key":"707_CR93","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40259-017-0252-3","volume":"31","author":"MI Aladul","year":"2017","unstructured":"Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017;31(6):533\u201344. https:\/\/doi.org\/10.1007\/s40259-017-0252-3.","journal-title":"BioDrugs"},{"issue":"10","key":"707_CR94","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2471\/BLT.16.187344","volume":"95","author":"A Ferrario","year":"2017","unstructured":"Ferrario A, Humbert T, Kanavos P, Pedersen HB. Strategic procurement and international collaboration to improve access to medicines. Bull World Health Organ. 2017;95(10):720\u20132. https:\/\/doi.org\/10.2471\/BLT.16.187344.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"707_CR95","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00228-019-02765-3","volume":"76","author":"TB Jensen","year":"2020","unstructured":"Jensen TB, Bartels D, Saedder EA, Poulsen BK, Andersen SE, Christensen MMH, et al. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Eur J Clin Pharmacol. 2020;76(1):35\u201340. https:\/\/doi.org\/10.1007\/s00228-019-02765-3.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"707_CR96","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40290-021-00396-7","volume":"35","author":"ST Oskouei","year":"2021","unstructured":"Oskouei ST, Kusmierczyk AR. Biosimilar uptake: the importance of healthcare provider education. Pharmaceut Med. 2021;35(4):215\u201324. https:\/\/doi.org\/10.1007\/s40290-021-00396-7.","journal-title":"Pharmaceut Med."},{"issue":"1","key":"707_CR97","doi-asserted-by":"publisher","first-page":"102","DOI":"10.18553\/jmcp.2019.25.1.102","volume":"25","author":"E Leonard","year":"2019","unstructured":"Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102\u201312. https:\/\/doi.org\/10.18553\/jmcp.2019.25.1.102.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"707_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034183","volume":"10","author":"K Sarnola","year":"2020","unstructured":"Sarnola K, Merikoski M, Jyrkka J, Hameen-Anttila K. Physicians\u2019 perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020;10(5): e034183. https:\/\/doi.org\/10.1136\/bmjopen-2019-034183.","journal-title":"BMJ Open"},{"issue":"2","key":"707_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000460","volume":"4","author":"R Giuliani","year":"2019","unstructured":"Giuliani R, Tabernero J, Cardoso F, McGregor KH, Vyas M, de Vries EGE. Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. ESMO Open. 2019;4(2): e000460. https:\/\/doi.org\/10.1136\/esmoopen-2018-000460.","journal-title":"ESMO Open."},{"issue":"1","key":"707_CR100","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40259-021-00509-3","volume":"36","author":"J Yang","year":"2022","unstructured":"Yang J, Blinzler K, Lankin J, Vijayakumar S, Maculaitis MC, Shelbaya A. Evolving perceptions, utilization, and real-world implementation experiences of oncology monoclonal antibody biosimilars in the USA: perspectives from both payers and physicians. BioDrugs. 2022;36(1):71\u201383. https:\/\/doi.org\/10.1007\/s40259-021-00509-3.","journal-title":"BioDrugs"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00707-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00707-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00707-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:47:11Z","timestamp":1741848431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00707-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00707-3","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"19 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by a grant of the Korean Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2024-00438476). Funding for the preparation of this article was provided by Samsung Bioepis Co., Ltd. (Incheon, Republic of Korea).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jun Ho Jang and Bing Han have no conflicts of interest that are directly relevant to the content of this article. Austin G. Kulasekararaj reports consultancy fees\/honoraria\/speaker\u2019s bureau fees from Achillion, Akari, Alexion, AstraZeneca Rare Disease, Amgen, Apellis, Biocryst, Celgene, F. Hoffmann-La Roche, Novartis, Pfizer, NovoNordisk, Samsung, Silence Therapeutics, and Ra Pharma and research funding from Celgene\/BMS and Novartis. Jinah Jung and Paola Russo are employees of Samsung Bioepis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"JHJ formulated the concept and JJ wrote the draft of the manuscript. All authors participated in editing and revising the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}